TradingHolo

The whole market. One view. Market data from our own platform. Not investment advice. Prices in listing currency with AED alongside; market cap in USD. Live = streaming now; Delayed 15 min where the exchange requires it; At close = last official close.

News Calendar Economy IPOs ETFs Account

⌂Home ◈Markets ▦Screener 📈Tools ◎Portfolio

Skip to content

DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100166,388.00+0.25%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 300.20+0.24%Gold$4,143.71+0.07%Brent$109.87+0.60%BTC$81,986.98+0.18%ETH$2,409.21+0.17%DFM General5,851.39−0.27%FTSE ADX9,783.24−0.26%TASI10,123.62−0.65%QE Index8,632.66−0.01%S&P 5007,690.73+0.41%Nasdaq 10029,529.34+1.17%Nifty 5022,888.95−1.11%Sensex73,852.90−1.17%KSE-100166,388.00+0.25%DFM:EMIRATESNBDAED 31.50−0.25%ADX:IHCAED 352.00−0.17%SAU:2222SAR 25.80+0.00%DSMD:QNBKQAR 15.66+2.29%NAS:NVDA$217.09+1.38%NYSE:TSM$420.22+1.84%NSE:RELIANCE₹1,202.00−0.76%KAR:OGDCRs 300.20+0.24%Gold$4,143.71+0.07%Brent$109.87+0.60%BTC$81,986.98+0.18%ETH$2,409.21+0.17%

Stock markets

🇦🇪UAEDFM · ADX · DFM GeneralClosed 🇸🇦Saudi ArabiaTadawul · TASIClosed 🇶🇦QatarQSE · QE GeneralClosed 🇺🇸United StatesNasdaq · NYSE · S&P 500Closed 🇮🇳IndiaNSE · BSE · Nifty 50Closed 🇵🇰PakistanPSX · KSE-100Open

Other assets

₿CryptoRanked by volume · 24/7 🥇Gold, FX & economyDubai gold, AED crosses, rates ◫ETFsIndex, sector and gold funds

Explore

▦Market mapEvery market as a heatmap 📅Calendar & IPOsEarnings, dividends, listings, releases ⌁Options flow · Ownership · PoliticsUS filings and tapes

⚲Stock screenerAll six markets, one row per company ★Ready-made screensStarting points with a point of view 📁My saved screensSaved rules with alerts on new matches ⇄CompareUp to five, side by side

📈ChartingDrawings, indicators, replay ▶Strategy MakerWrite a rule, test it on history ⇄CompareSide by side 🔔AlertsPrice, earnings, screens, strategies

⌕

Sign in Create account👤

Markets › United States › NAS › ARQT

A

Arcutis Biotherapeutics Inc

NAS:ARQTHealthcareCBOEFTSE:MRUTNASDAQ:NBI

$31.89+10.65%At closeAt close · Tue 20 Oct · ≈ AED 117.12 · Market cap $4.01B · Next earnings Tue 27 Oct

🔔 Alert▶ Test a strategy

Overview Chart Financials Valuation Forecasts Dividends Ownership Options Shorts News Profile

Arcutis Biotherapeutics Inc · Overview · TradingHolo

1D

+10.7%

1M

+25.7%

3M

+12.8%

6M

+30.3%

1Y

+52.5%

Why it's moving today

Arcutis Biotherapeutics Price Target Raised to $44.00/Share From $38.00 by Guggenheim

Dow Jones Newswires · Mon 19 Oct

✦ This week in three lines

No written digest yet for ARQT. The figures on this page are the source when one is written.

Financials

USD millions · annual5Y CAGR —

Valuation

P/E vs sector−248.3× vs −1.7×

Price / Book vs sector21.2× vs 2.0×

Price / Sales vs sector10.7× vs 3.9×

Price / Free cash flow vs sector−635.1× vs −1.5×

Forecasts

7 buy1 hold0 sell8 analysts

Average target$38.00 +19.2%

Analysts2

EPS surprises, last 87 beats

Dividends

Yield0.0%

Annual payout—

Payout ratio0.0%

Next ex-date—

Years of growth—

Latest news

All ARQT news →

DOArcutis Biotherapeutics Price Target Raised to $44.00/Share From $38.00 by Guggenheim

Dow Jones Newswires · 12 h ago

DOArcutis Biotherapeutics Initiated at Overweight by Cantor Fitzgerald

Dow Jones Newswires · 4 d ago

SEArcutis jumps as Cantor issues new Overweight citing lead product

Seeking Alpha · 5 d ago

Key facts

At close · Tue 20 Oct

Market cap (USD)$4.01B

P/E−248.3×

Dividend yield0.0%

52-week range$19.30 – $33.01

Avg volume (20d)2,449,485

Shares outstanding125,692,000

Beta1.53

Short interest19.8% of float

Next earningsTue 27 Oct

Radar Score

58

Value37

Quality67

Momentum85

Income45

Peer percentile within United States Healthcare0–100 · null when more than one input is missing

About

Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating…

SectorHealthcare

IndustryNormal

ExchangeNAS

Peers

LLNYSE:LLYEli Lilly and Co · 🇺🇸 NYSE

56.6×−1.33%

JNNYSE:JNJJohnson & Johnson · 🇺🇸 NYSE

22.8×−0.69%

ABNYSE:ABBVAbbVie Inc · 🇺🇸 NYSE

118.2×−0.96%

UNNYSE:UNHUnitedHealth Group Inc · 🇺🇸 NYSE

30.3×+1.36%